The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Scaffold thrombosis: what is to blame?

EuroIntervention 2021;17:e955-e957. DOI: 10.4244/EIJV17I12A159

1. Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA
Bioresorbable scaffolds (BRS) were originally designed on the premise that the absence of a permanent metallic cage would mitigate late adverse events such as late stent thrombosis and restenosis, and would fully restore vasomotor and endothelial function of the vessel, inducing luminal gain and atherosclerotic plaque passivation1. Meanwhile, drug-eluting-stent (DES) technology continued to improve the short- and long-term outcomes of percutaneous coronary intervention (PCI) and challenged the merits of BRS. Absorb (Abbott Laboratories, Inc.), a first-generation poly-L-lactic acid (PLLA)-based BRS, was approved for marketing and taken to trials against the best-in-class DES. Whilst the initial results at one-year follow-up ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Planning percutaneous interventions with optical flow ratio: “niu” odds in favour of imaging in the year of the Ox